BACKGROUND: Daratumumab-based combination therapies have shown high rates of complete response (CR) and minimal residual disease negativity in patients with multiple myeloma. However, daratumumab, an IgGκ monoclonal antibody, interferes with electrophoretic techniques making it difficult to reliably define residual disease versus CR, especially in patients with IgGκ multiple myeloma. METHODS: Enrichment with polyclonal sheep antibody-coated magnetic microparticles combined with MALDI-TOF mass spectrometry (MALDI-TOF MS) analysis was used to detect M-proteins in serial samples from newly diagnosed multiple myeloma patients treated with daratumumab-based therapy. The performance of the MALDI-TOF MS assay was compared to that of a routine test panel (serum protein electrophoresis (SPEP), immunofixation (IFE) and serum free light chain (FLC)). RESULTS: Comparison of MALDI-TOF MS to SPEP/IFE/FLC showed a concordance of 84.9% (p < 0.001). When MALDI-TOF MS and FLC results were combined, the M-protein detection rate was the same or better than the routine test panel. For the 9 patients who obtained CR during follow-up, MALDI-TOF MS detected an M-protein in 46% of subsequent samples. Daratumumab could be distinguished from the M-protein in 215/222 samples. CONCLUSION: MALDI-TOF MS is useful in assessing CR in patients treated with monoclonal antibody-based therapies.
BACKGROUND: Daratumumab-based combination therapies have shown high rates of complete response (CR) and minimal residual disease negativity in patients with multiple myeloma. However, daratumumab, an IgGκ monoclonal antibody, interferes with electrophoretic techniques making it difficult to reliably define residual disease versus CR, especially in patients with IgGκ multiple myeloma. METHODS: Enrichment with polyclonal sheep antibody-coated magnetic microparticles combined with MALDI-TOF mass spectrometry (MALDI-TOF MS) analysis was used to detect M-proteins in serial samples from newly diagnosed multiple myeloma patients treated with daratumumab-based therapy. The performance of the MALDI-TOF MS assay was compared to that of a routine test panel (serum protein electrophoresis (SPEP), immunofixation (IFE) and serum free light chain (FLC)). RESULTS: Comparison of MALDI-TOF MS to SPEP/IFE/FLC showed a concordance of 84.9% (p < 0.001). When MALDI-TOF MS and FLC results were combined, the M-protein detection rate was the same or better than the routine test panel. For the 9 patients who obtained CR during follow-up, MALDI-TOF MS detected an M-protein in 46% of subsequent samples. Daratumumab could be distinguished from the M-protein in 215/222 samples. CONCLUSION: MALDI-TOF MS is useful in assessing CR in patients treated with monoclonal antibody-based therapies.
Authors: Taxiarchis Kourelis; David L Murray; Surendra Dasari; Sanjay Kumar; David Barnidge; Benjamin Madden; Bonnie Arendt; Paolo Milani; Giampaolo Merlini; Marina Ramirez-Alvarado; Robert A Kyle; Angela Dispenzieri Journal: Am J Hematol Date: 2018-09-21 Impact factor: 10.047
Authors: Marina Zajec; Joannes F M Jacobs; Patricia J T A Groenen; Corrie M de Kat Angelino; Christoph Stingl; Theo M Luider; Yolanda B De Rijke; Martijn M VanDuijn Journal: J Proteome Res Date: 2018-02-15 Impact factor: 4.466
Authors: Thierry Facon; Shaji Kumar; Torben Plesner; Robert Z Orlowski; Philippe Moreau; Nizar Bahlis; Supratik Basu; Hareth Nahi; Cyrille Hulin; Hang Quach; Hartmut Goldschmidt; Michael O'Dwyer; Aurore Perrot; Christopher P Venner; Katja Weisel; Joseph R Mace; Noopur Raje; Michel Attal; Mourad Tiab; Margaret Macro; Laurent Frenzel; Xavier Leleu; Tahamtan Ahmadi; Christopher Chiu; Jianping Wang; Rian Van Rampelbergh; Clarissa M Uhlar; Rachel Kobos; Ming Qi; Saad Z Usmani Journal: N Engl J Med Date: 2019-05-30 Impact factor: 91.245
Authors: Paolo Milani; David L Murray; David R Barnidge; Mindy C Kohlhagen; John R Mills; Giampaolo Merlini; Surendra Dasari; Angela Dispenzieri Journal: Am J Hematol Date: 2017-06-01 Impact factor: 10.047
Authors: Kazunori Murata; Samuel I McCash; Brittany Carroll; Alexander M Lesokhin; Hani Hassoun; Nikoletta Lendvai; Neha S Korde; Sham Mailankody; Heather J Landau; Guenther Koehne; David J Chung; Sergio A Giralt; Lakshmi V Ramanathan; Ola Landgren Journal: Clin Biochem Date: 2016-09-21 Impact factor: 3.281
Authors: Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau Journal: Lancet Oncol Date: 2016-08 Impact factor: 41.316
Authors: Noemí Puig; María-Teresa Contreras; Cristina Agulló; Joaquín Martínez-López; Albert Oriol; María-Jesús Blanchard; Rafael Ríos; Jesús Martín; María-Belén Iñigo; Anna Sureda; Miguel-Teodoro Hernández; Javier de la Rubia; Verónica González-Calle; Isabel Krsnik; Valentín Cabañas; Luis Palomera; José-María Moraleda; Joan Bargay; María-Teresa Cedena; Bruno Paiva; Laura Rosiñol; Joan Bladé; Jesús San Miguel; Juan-José Lahuerta; María-Victoria Mateos Journal: Blood Adv Date: 2022-06-14